Trospium Chloride Tablet, Film Coated
Product Images NDC 76282-336

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 76282-336). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
This is a graph that shows the plasma concentration (measured in ng/mL) of a substance over time (measured in hours post-dose). The x-axis shows the time post-dose ranging from 0 to 48 hours, and the y-axis shows the plasma concentration ranging from 0 to 50 ng/mL.*
FDA Label Image

Structure (Trospium 01)

Structure (Trospium 01)
FDA Label Image

Trospium-chloride-20mg (Trospium Chloride 20mg)

Trospium-chloride-20mg (Trospium Chloride 20mg)
Exelan Trospium Chloride Tablets, USP 20mg is a prescription medication used to treat overactive bladder symptoms such as urinary incontinence, urgency, and frequency. Each package contains 60 film-coated tablets that should be stored at 20°to 25° 68° to 77°F. Patients must follow the instructions on the Patient Information Leaflet provided separately by the pharmacist. Exelan Trospium Chloride Tablets should be kept in a tight container and away from children. It is manufactured by InvaGen Pharmaceuticals, a subsidiary of Cipla Ltd, and distributed by Exelan Pharmaceuticals, Inc. in Boca Raton, FL. For complete prescribing information, read the package insert.*
FDA Label Image

Figure2 (Trospium Fig2)

Figure2 (Trospium Fig2)
Figure 2 shows the Mean Change from Baseline in Urinary Frequency/24 Hours, by Visit for Study 1. The data includes a placebo group of 256 participants and a Trospium Chloride group of 253 participants. The week of treatment is displayed along the bottom axis, with the y-axis indicating the mean change in urinary frequency. Statistical significance is denoted by p-values displayed above the bars.*
FDA Label Image

Figure3 (Trospium Fig3)

Figure3 (Trospium Fig3)
The text describes a figure titled "Figure 3," which shows the mean change from baseline in urge incontinence per week in Study 1. The figure compares results between a placebo group and a group taking Trospium Chloride (N=253). The figure shows the mean (+SE) change at different weeks of treatment. There is a significant decrease in urge incontinence in the Trospium Chloride group at week 16 (p=0.003) and week 48 (p=0.012).*
FDA Label Image

Fig4 (Trospium Fig4)

Fig4 (Trospium Fig4)
This is a figure showing the change from baseline in urinary frequency per 24 hours for Study 2. The x-axis represents the week of treatment, while the y-axis shows the mean change with standard error bars. The study included 326 participants on placebo and 323 participants on Sanctura®. There is no additional information available.*
FDA Label Image

Figure5 (Trospium Fig5)

Figure5 (Trospium Fig5)
The graph in Figure 5 shows the mean change from baseline in urge incontinence per week over the course of treatment for Study 2. The study includes a placebo group with 325 participants and a group receiving Sanctura with 323 participants. It appears that there is a significant mean improvement in urge incontinence for the Sanctura group compared to the placebo group starting around week 2 of treatment.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.